Search

Displaying results 8461 - 8470 of 10000 in total
  1. Drug

    Pralsetinib

    go.drugbank.com/drugs/DB15822
    ApprovedInvestigational

    [A202049, A202055, L15986] Although a phase 1/2 trial of pralsetinib termed ARROW (NCT03037385) is still ongoing, pralsetinib was granted accelerated FDA approval on September 4, 2020, for the treatment … It is currently marketed under the brand name GAVRETO™ by Blueprint Medicines.[L15986]

    Categories: MATE 1 Inhibitors, MATE 2 Inhibitors
  2. Drug

    Ferrimannitol ovalbumin

    go.drugbank.com/drugs/DB15824
    Investigational

    Ferrimannitol-ovalbumin (FMOA) is an adduct between ovalbumin and the complex Fe(III)-mannitol.

  3. Drug

    Cedar leaf oil

    go.drugbank.com/drugs/DB15836
    Investigational

    Mixtures: KATALJİN BUHARLAŞAN MERHEM, 40 G, KATALJİN BUHARLAŞAN MERHEM, 12,5 G
  4. Drug

    Sodium metabisulfite

    go.drugbank.com/drugs/DB15842
    Investigational

    Mixtures: NEOFLEKS IZOPLEN-M % 5 DEKSTROZLU DENGELI ELEKTROLIT IÇEREN INFÜZYON IÇIN ÇÖZELTI 1000 ML SETLI, NEOFLEKS IZOPLEN-M % 5 DEKSTROZLU DENGELI ELEKTROLIT IÇEREN INFÜZYON IÇIN ÇÖZELTI 1000 ML SETSIZ
  5. Drug

    Zorecimeran

    go.drugbank.com/drugs/DB15843
    Investigational

    The CVnCov Vaccine (or CV07050101) is in development by CureVac AG. … As of June 2020, the company received regulatory approval from German and Belgian Authorities to commence Phase 1 clinical trials of this vaccine (NCT04449276).

  6. Drug

    COVID-19 Nucleocapsid-GM-CSF Protein Lactated Ringer's Injection

    go.drugbank.com/drugs/DB15845
    Experimental

    As of July 2020, Medicine Invention Design, Inc. is sponsoring a small, controlled clinical trial for the COVID-19 AP TP Vaccine for ‘proof of concept.’ … The vaccine utilizes granulocyte macrophage-colony stimulating factor (GM-CSF), a cytokine known to enhance vaccine efficacy through prolongation of humoral and cell immunity.

    Synonyms: AP-TP-V
  7. Drug

    IMM101

    go.drugbank.com/drugs/DB15851
    Experimental

    IMM-101 is a heat-inactivated immune-activating mycobacterial product. … As of July 2020, researchers from the Ottawa Hospital and Queen’s University, in partnership with the Canadian Cancer Society-funded Canadian Cancer Trials Group (CCTG), are conducting a trial in over

  8. Drug

    AG0301-COVID19

    go.drugbank.com/drugs/DB15856
    Investigational

    AG0301-COVID19 is a vaccine candidate developed by AnGes Inc. and Osaka University. … The candidate is a plasmid DNA vaccine developed using an intradermal gene transfer method targeting the SARS-CoV-2 spike protein.

  9. Drug

    Inactivated SARS-CoV-2 Vaccine (Chinese Academy of Medical Sciences)

    go.drugbank.com/drugs/DB15863
    Experimental

    The SARS-CoV-2 Inactivated Vaccine is a purified vaccine that contains multiple antigens from the virus and is inactivated in Vero Cells[A219758]. … As of June, 2020, safety and Immunogenicity trials are currently underway for this vaccine (NCT04470609 & NCT04412538).

  10. Drug

    Oral Polio Vaccine

    go.drugbank.com/drugs/DB15864
    Investigational

    The polio vaccine can be either administered in the inactivated form or the oral form, although both series comprises 4 doses and is also interchangeable in administration form so long all as 4 doses are … The oral polio vaccine (OPV) is a live attenuated vaccine containing a mixture of one or more strains of poliovirus serotypes.